Dopamine D1 receptor expression in human basal ganglia and changes in Parkinson's disease

Molecular Brain Research

Volumn 87, Issue 2, 2001, Pages 271-279

  Hurley, Michael J ^a,c   Mash, Deborah C ^a   Jenner, Peter ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Basal ganglia; Dopamine D1 receptor; Parkinson's disease; Radioligand binding; RT PCR

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE RECEPTOR; LEVODOPA; MESSENGER RNA; RADIOLIGAND;

ARTICLE; AUTOPSY; BASAL GANGLION; BINDING SITE; BRAIN REGION; BRAIN TISSUE; CAUDATE NUCLEUS; CONTROLLED STUDY; DYING; GLOBUS PALLIDUS; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; AGED; AGED, 80 AND OVER; BASAL GANGLIA; BRAIN CHEMISTRY; DOPAMINE ANTAGONISTS; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRITIUM;

PARKINSONIA;

EID: 0035809803     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(01)00022-5     Document Type: Article

References (60)

1. Basic local alignment search tool
2. The selective dopamine D1 receptor agonist A-86929 maintains efficacy with repeated treatment in rodent and primate models of Parkinson's disease
3. Dopamine-containing systems in the CNS
4. Differential effects of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys
5. Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia?
6. 3H]-Spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy
7. Selective D1 dopamine receptor agonist treatment of Parkinson's disease
8. What do the basal ganglia do?
9. Dopamine D-1 receptor and cyclic AMP-dependent phosphorylation in Parkinson's disease
10. Failure of SKF38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset
11. Dopamine receptors in human brain: Autoradiographic distribution of D1 and D2 sites in Parkinson syndrome of different etiology
12. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: Implications for future strategies in treatment
13. Primate models of movement disorders of basal ganglia origin
14. Selective full dopamine D1-like (SKF-82958) and D2-like (N-0923) agonist combination in the MPTP monkey model of hemiparkinsonism
15. Internalization of D1 dopamine receptor in striatal neurons in vivo as evidence of activation by dopamine agonists
16. Effects of a selective partial D1 agonist CY 208-243 in de novo patients with Parkinson's disease
17. Expression of dopamine receptors in the subthalamic nucleus of the rat: Characterization using reverse transcriptase-polymerase chain reaction and autoradiography
18. Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I. Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors
19. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism
20. Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: An acute study in parkinsonian levodopa-primed monkeys
21. Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain
22. Dopamine (3-hydroxytyramine) and brain function
23. Biochemical aspects of Parkinson's disease
24. Distributional maps of tyrosine-hydroxylase-immunoreactive neurons in the rat brain
25. A-77636: A potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets
26. Apomorphine and dopamine D(1) receptor agonists increase the firing rates of subthalamic nucleus neurons
27. Mapping of D1 dopamine receptor mRNA by non-radioactive in situ hybridization
28. Receptor basis for dopaminergic supersensitivity in Parkinson's disease
29. Parkinson's disease: Low density and presynaptic location of D3 receptors
30. Localization of D1 and D2 dopamine receptor in brain with subtype-specific antibodies
31. Dopaminergic innervation of the globus pallidus by collaterals from the nigrostriatal pathway
32. A comparison of D1 receptor binding and mRNA in rat brain using receptor autoradiographic and in situ hybridization techniques
33. Parkinson's disease
34. Comparison of the distributions of D1 and D2 dopamine receptor mRNAs in rat brain
35. Visualization of a dopamine D1 receptor mRNA in human and rat brain
36. Visualization of dopamine D1, D2 and D3 receptor mRNAs in human and rat brain
37. Treatment of Parkinson's disease should begin with a dopamine agonist
38. Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease
39. The dopaminergic nigropallidal projection in primates: Distinct cellular origin and relative sparing in MPTP-treated monkeys
40. Chronic L-DOPA administration induces dyskinesias in the MPTP-treated common marmoset (Callithrix jacchus)
41. Actions of the D1 agonists A-77636 and A86929 on locomotion and dyskinesia in MPTP-treated L-DOPA-primed common marmosets
42. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy
43. 3H]-SCH23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease
44. 3H]-spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager syndrome
45. 3H]-SCH23390 to D-1 receptors in the putamen of control and parkinsonian subjects
46. Dopamine D-1 receptors in the parkinsonian brain
47. Human brain D-1 and D-2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's and Huntington's diseases
48. Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: A positron emission tomography study
49. ABT-431: The diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: In vitro characterization and effects in animal models of Parkinson's disease
50. Getting the message from the gene to the synapse: Sorting intracellular transport of RNA in neurons
51. Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys
52. Antiparkinsonian activity of CY 208-243, a partial D1 dopamine agonist, in MPTP-treated marmosets and patients with Parkinson's disease
53. Microtopography of D1 dopaminergic binding sites in human substantia nigra: An autoradiographic study
54. In vivo studies on striatal dopamine D1 and D2 site binding in L-DOPA-treated Parkinson's disease patients with and without dyskinesias
55. Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders
56. The dopamine D1 agonist SKF81297 and the dopamine D2 agonist LY17155 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys
57. D1 and D2 dopamine receptor mRNA in rat brain
58. Comparison of efficacy and dyskinesia-inducing potential of levodopa and ABT-431, a selective, full dopamine D1 receptor agonist
59. Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: Light and electron microscopy
60. Pharmacological and molecular evidence for dopamine D(1) receptor expression by striatal astrocytes in culture